Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group
复制标题
DOI：
10.1002/ajh.23923
复制
发表时间：
2015-04-01
影响因子：
12.8
通讯作者：
Sakamaki, Hisashi
中科院分区：
文献类型：
--
作者：
Iriyama, Noriyoshi;Fujisawa, Shin;Sakamaki, Hisashi
为了研究影响达沙替尼治疗慢性期慢性粒细胞白血病（CML-CP）患者的分子反应的因素，我们进行了一项名为D-First研究的临床试验。52例新诊断的CML-CP患者入组本研究，接受100 mg达沙替尼每日一次治疗。深度分子反应（DMR）定义为
To investigate the factors that affect molecular responses on dasatinib treatment in patients with chronic-phase chronic myeloid leukemia (CML-CP), we performed a clinical trial named the D-First study. Fifty-two patients with newly diagnosed CML-CP were enrolled in this study and received 100 mg dasatinib once daily. A deep molecular response (DMR) was defined as